Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer

Life Sciences

Volumn 130, Issue , 2015, Pages 73-80

  Thummuri, Dinesh ^a   Kumar, Sandeep ^a   Surapaneni, Sunil Kumar ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Epigenetics and DNA methylation; Hypomethylation; Triple negative breast cancer

Indexed keywords

AZACITIDINE; DNA METHYLTRANSFERASE 1; MESSENGER RNA; MICRORNA 124; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 12; UVOMORULIN; ANTINEOPLASTIC ANTIMETABOLITE; PTPN12 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 12; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84927949872     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.03.016     Document Type: Article

References (50)

1. C.K. Anders, and L.A. Carey Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin. Breast Cancer 9 2009 S73 S81
2. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
3. X. Cao, Y. Li, R.-Z. Luo, L.-R. He, J. Yang, and M.-S. Zeng et al. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma Ann. Thorac. Surg. 93 2012 1674 1680
4. F. Ciardiello, and G. Tortora Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs Eur. J. Cancer 39 2003 1348 1354
5. S. Cleator, W. Heller, and R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol. 8 2007 235
6. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J. Clin. Oncol. 28 2010 1075 1083
7. P.M. Das, and R. Singal DNA methylation and cancer J. Clin. Oncol. 22 2004 4632 4642
8. R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, and C.A. Sawka et al. Triple-negative breast cancer: clinical features and patterns of recurrence Clin. Cancer Res. 13 2007 4429 4434
9. M. Esteller Epigenetics in cancer N. Engl. J. Med. 358 2008 1148 1159
10. A.C. Ferguson-Smith, and M.A. Surani Imprinting and the epigenetic asymmetry between parental genomes Science 293 2001 1086 1089
11. A.T. Ferguson, P.M. Vertino, J.R. Spitzner, S.B. Baylin, M.T. Muller, and N.E. Davidson Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-Aza-2′ deoxycytidine-induced cytotoxicity in human breast cancer cells J. Biol. Chem. 272 1997 32260 32266
12. C. Garcia-Echeverria, and W.R. Sellers Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 27 2008 5511 5526
13. B.G. Haffty, Q. Yang, M. Reiss, T. Kearney, S.A. Higgins, and J. Weidhaas et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J. Clin. Oncol. 24 2006 5652 5657
14. E. Heard Recent advances in X-chromosome inactivation Curr. Opin. Cell Biol. 16 2004 247 255
15. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N. Engl. J. Med. 349 2003 2042 2054
16. M.V. Iorio, M. Ferracin, C.-G. Liu, A. Veronese, R. Spizzo, and S. Sabbioni et al. MicroRNA gene expression deregulation in human breast cancer Cancer Res. 65 2005 7065 7070
17. M.V. Iorio, M. Ferracin, C.-G. Liu, A. Veronese, R. Spizzo, and S. Sabbioni et al. MicroRNA gene expression deregulation in human breast cancer Cancer Res. 65 2005 7065 7070
18. S.T. Jacob, and T. Motiwala Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy Cancer Gene Ther. 12 2005 665 672
19. D.G. Kabra, J. Gupta, and K. Tikoo Insulin induced alteration in post-translational modifications of histone H3 under a hyperglycemic condition in L6 skeletal muscle myoblasts BBA Mol. Basis Dis. 1792 2009 574 583
20. D.G. Kabra, J. Gupta, and K. Tikoo Insulin induced alteration in post-translational modifications of histone H3 under a hyperglycemic condition in L6 skeletal muscle myoblasts BBA Mol. Basis Dis. 1792 2009 574 583
21. F. Kamangar, G.M. Dores, and W.F. Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J. Clin. Oncol. 24 2006 2137 2150
22. S. Kashiwagi, M. Yashiro, T. Takashima, S. Nomura, S. Noda, and H. Kawajiri Significance of E-cadherin expression in triple-negative breast cancer Br. J. Cancer 103 2010 249 255
23. F.S. Kenny, P.C. Willsher, J.M.W. Gee, R.I. Nicholson, S.E. Pinder, and I.O. Ellis et al. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer Breast Cancer Res. Treat. 65 2001 135 144
24. T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, and N. Shiraishi et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells Mol. Cancer Ther. 6 2007 1718 1727
25. T. Mahmoudi, and C.P. Verrijzer Chromatin silencing and activation by polycomb and trithorax group proteins Oncogene 20 2001 3055
26. E.L. Mayer, A.H. Partridge, L.N. Harris, R.S. Gelman, S.T. Schumer, and H.J. Burstein et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer Breast Cancer Res. Treat. 117 2009 615 623
27. S. Meiners, V. Brinkmann, H. Naundorf, and W. Birchmeier Role of morphogenetic factors in metastasis of mammary carcinoma cells Oncogene 16 1998 9
28. A.A. Midland, M.C. Whittle, J.S. Duncan, A.N. Abell, K. Nakamura, and J.S. Zawistowski et al. Defining the expressed breast cancer kinome Cell Res. 22 2012 620 623
29. S. Mirza, G. Sharma, P. Pandya, and R. Ralhan Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents Mol. Cell. Biochem. 342 2010 101 109
30. G.J. Morris, S. Naidu, A.K. Topham, F. Guiles, Y. Xu, and P. McCue et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients Cancer 110 2007 876 884
31. T. Motiwala, K. Ghoshal, A. Das, S. Majumder, D. Weichenhan, and Y.Z. Wu et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas Oncogene 22 2003 6319 6331
32. T. Motiwala, H. Kutay, K. Ghoshal, S. Bai, H. Seimiya, and T. Tsuruo et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer Proc. Natl. Acad. Sci. U. S. A. 101 2004 13844 13849
33. S.J. Nass, J.G. Herman, E. Gabrielson, P.W. Iversen, F.F. Parl, and N.E. Davidson et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer Cancer Res. 60 2000 4346 4348
34. A. Ostman, and F.D. Bohmer Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases Trends Cell Biol. 11 2001 258 266
35. A. Ostman, C. Hellberg, and F.D. Bohmer Protein-tyrosine phosphatases and cancer Nat. Rev. Cancer 6 2006 307 320
36. L. Overbergh, A. Giulietti, D. Valckx, B. Decallonne, R. Bouillon, and C. Mathieu The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression J. Biomol. Tech. 14 2003 33
37. L. Overbergh, A. Giulietti, D. Valckx, B. Decallonne, R. Bouillon, and C. Mathieu The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression J. Biomol. Tech. 14 2003 33
38. C.M. Perou, T. Sarlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
39. F. Rajaii, L. Asnaghi, R. Enke, S.L. Merbs, J.T. Handa, and C.G. Eberhart The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma Invest. Ophthalmol. Vis. Sci. 55 2014 6178 6186
40. B. Ramaswamy, S. Majumder, S. Roy, K. Ghoshal, H. Kutay, and J. Datta et al. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity Mol. Endocrinol. 23 2009 176 187
41. K.E. Reeder-Hayes, L.A. Carey, and W.M. Sikov Clinical trials in triple negative breast cancer Breast Dis. 32 2010 123 136
42. M.-F. Robert, S. Morin, N. Beaulieu, F. Gauthier, I.C. Chute, and A. Barsalou et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells Nat. Genet. 33 2002 61 65
43. L.R. Saunders, A.D. Sharma, J. Tawney, M. Nakagawa, K. Okita, and S. Yamanaka et al. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues Aging 2 2010 415 431
44. C. Sotiriou, S.-Y. Neo, L.M. McShane, E.L. Korn, P.M. Long, and A. Jazaeri et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc. Natl. Acad. Sci. U. S. A. 100 2003 10393 10398
45. T. Sun, N. Aceto, K.L. Meerbrey, J.D. Kessler, C. Zhou, and I. Migliaccio et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase Cell 144 2003 703 718
46. C. Teixeira, J.C. Reed, and M.A.C. Pratt Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells Cancer Res. 55 1995 3902 3907
47. F. Trapasso, S. Yendamuri, K.R. Dumon, R. Iuliano, R. Cesari, and B. Feig et al. Restoration of receptor-type protein tyrosine phosphatase η·function inhibits human pancreatic carcinoma cell growth in vitro and in vivo Carcinogenesis 25 2004 2107 2114
48. H.C. Tsai, H. Li, L. Van Neste, Y. Cai, C. Robert, and F.V. Rassool et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Cell 21 2012 430 446
49. R. van Doorn, W.H. Zoutman, R. Dijkman, R.X. de Menezes, S. Commandeur, and A.A. Mulder et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73 J. Clin. Oncol. 23 2005 3886 3896
50. L. Yang, X. Wu, Y. Wang, K. Zhang, J. Wu, and Y.C. Yuan et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer Oncogene 30 2011 4437 4446